A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's disease (Including Systemic Juvenile Idiopathic Arthritis and Adult onset Still's disease) or with MAS in Systemic Lupus Erythematous
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Emapalumab (Primary)
- Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis; Macrophage activation syndrome; Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms EMERALD; NI0501-14
- Sponsors Swedish Orphan Biovitrum
- 19 Sep 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 18 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.
- 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.